Pfizer Faces Cautious Turn After Downgrade and Pipeline Update

Pfizer US7170811035

Pfizer?s stock took a modest step back this week as a rating shift from a prominent broker underscored a more conservative stance on the shares. The move followed a brisk rally that had just produced a fresh 52-week high, giving way to a valuation-first narrative from at least one analyst.

• Daiwa (Thursday): downgrade from ?Outperform? to ?Neutral,? with a $27.00 price target
• New 52?week high (Tuesday): $27.73
• Outlook for 2026: revenue guidance $59.5 to $62.5 billion, with flat operational growth
• Pipeline update: FDA Priority Review for Hympavzi expansion, decision expected in Q2 2026

Daiwa?s downgrade on Thursday trimmed the rating to Neutral and set a $27.00 target. The timing stands out: Pfizer had just reached a fresh intrayearly high of $27.73 a day earlier, suggesting Daiwa views the rally as largely justified by near-term momentum rather than ongoing upside.

Additionally, Freedom Capital Markets adjusted its view this week as well. On Monday, the firm reduced its price target from $35.00 to $33.00, while maintaining a Buy rating. The rationale cited ongoing pressure from declining sales of COVID-related products.

Solid Q4 results, but a restrained 2026 path

Pfizer?s recent quarterly performance topped expectations. In the fourth quarter of 2025, the company reported $17.56 billion in revenue and $0.66 per share.

For 2026, Pfizer?s management guided revenue to be in the range of $59.5 to $62.5 billion, with flat operational growth included in the outlook. The guidance factors in anticipated declines in COVID-related products and the effects of patent expirations on key medicines.

Pipeline milestone: Hympavzi under Priority Review

In development news, the U.S. FDA granted a Priority Review for the supplemental Biologics License Application (sBLA) for Hympavzi (marstacimab). The aim is to broaden the approval to treat certain pediatric patients with hemophilia A or B. The FDA is targeting a decision in Q2 2026.

Look-ahead notes

• In the near term, investors will weigh valuation concerns against the modest upside from the stock?s recent rally and the evolving COVID?related product tailwinds.
• In the medium term, the FDA decision on Hympavzi in Q2 2026 looms as a potential catalyst.
• For 2026, Pfizer?s revenue guidance sits within a range of $59.5 to $62.5 billion, with expectations for flat operating growth.